No Data
Stoke Therapeutics(STOK.US) 10% Shareholder Sells US$23 Million in Common Stock
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
Express News | Form 144 | Stoke Therapeutics(STOK.US) Insider Proposes to Sell 23.18 Million in Common Stocks
Leerink Partners Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $24
Stoke Therapeutics Initiated at Buy by Chardan Capital
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
